Researchers at the German Heart Centre and 1 Clinic at the hospital right of the Isar.

Isoosmolartudy: To what extent high-risk patients benefit from the Renal tolerance iso-osmolar X – Ray Contrast Media?Researchers at the German Heart Centre and 1 Clinic at the hospital right of the Isar , both in Munich examined for the first time the cardiac and renal tolerance of contrast media with different osmolarities in a high-risk group of patients with chronic renal failure, percutaneous coronary intervention.

The Company intends to becomes blurred.n wet AMD in the fourth quarter 2006 launch.. About MacuSightMacuSight a privately-held pharmaceutical focused focused on developing innovative therapeutics for the treatment of serious eye diseases and conditions. The company ‘s own vision for the conservation of patient by identifying known, highly – potent and broad -acting small molecule drug compounds, the effective in the treatment and / or prevention of diseases or conditions of the eye can be devoted. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye.Non small cell lung Technology identifies two biomarkers Connected Lung Cancer Survival and.

Tall expression of combined of the RRM1 and of ERCC1 proteins it was shown that an increased risk of lung cancer survival be associated, according to a study by researchers from the B. Lee Moffitt Cancer Center & Research Institute, published in today issue of the New England Journal of Medicine. The survey is in its 22nd February 2007 issue of New England Journal of Medicine co-authors of the study include Zhong Zheng, Tingan Chen, Xueli Li, Eric Haura, Anupama Sharma and Gerold Bepler.

You may also like